Skip to main navigation News Releases Year 2021 Nov 22, 2021 Sorrento Therapeutics Mexico Executes Contract for Sale of 5 Million COVI-STIX Tests for Mexico Market Nov 12, 2021 Sorrento Therapeutics Mexico to Partner with the World Boxing Council for the Screening of COVID-19 of all Convention Attendees with COVI-STIX at the 59th World Boxing Council Convention in Mexico City Nov 12, 2021 Sorrento Announces Publication of Significant Positive Pivotal Trial Results of Abivertinib for the Treatment of Non-Small Cell Lung Cancer (NSCLC) in the Peer-Reviewed Journal Clinical Cancer Research Nov 07, 2021 Sorrento Awarded California Competes Tax Credit Nov 03, 2021 Sorrento Receives Brazilian Health Regulatory Agency (ANVISA) Approval for COVISTIX™ (COVID-19 Virus Antigen Detection Test) for Brazil Nov 01, 2021 Sorrento’s License Partner, Lee’s Pharmaceutical Announces NDA Filing Acceptance by NMPA for Anti-PD-L1 Antibody Socazolimab for Treatment of Recurrent or Metastatic Cervical Cancer Oct 27, 2021 UPDATE – Sorrento Announces Encouraging Results From Two Phase 2 Studies of Abivertinib For Treatment Of Hospitalized Severe COVID-19 Patients Oct 27, 2021 Sorrento Announces Encouraging Results From Two Phase 2 Studies of Abivertinib For Treatment Of Hospitalized Severe COVID-19 Patients Oct 20, 2021 Sorrento Announces That COVISTIX™ (COVID-19 Virus Rapid Antigen Detection Test) Has Received a CE Mark and Registration of the Device Oct 13, 2021 Sorrento Receives FDA Clearance to Proceed With Clinical Trial for Anti-TROP-2 Antibody Drug Conjugate (TROP-2 ADC) for multiple solid tumors Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Next page next › Last page last » Tools PRINT EMAIL ALERTS RSS FEEDS EMAIL PAGE © 2021 Sorrento Therapeutics. All Rights Reserved. Footer Terms of Use Privacy Policy DMCA Trademarks Linking Policy